Steven R. Pollock

APP Pharmaceuticals, Inc. develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. It offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. The company is headquartered in Los Angeles, CA.

SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI.

Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI.

Actient Pharmaceuticals LLC develops and markets pharmaceutical therapeutic products. The company was founded in March 2009 and is headquartered in Malvern, VA.

Flex Biomedical, Inc. develops novel treatments and diagnostics for orthopedic diseases. Its products are synthetic polymers which are designed to treat osteoarthritis, an incurable joint disease. The company was founded by Sal Braico, Hideki Suzuki, Mark W. Grinstaff, Michel Wathier and Brian Snyder in 2007 and is headquartered in Madison, WI.